TuesdayJan 23, 2024 12:44 pm

Novel Brain Scan Technique Exposes Vulnerability of Gliomas

A South Korean research team has discovered a novel brain scan technique that has the potential to revolutionize glioblastoma diagnosis and treatment. Led by Severance Hospital’s Professor Yun Mijin and Director C. Justin Lee from the Center for Cognition and Sociality, the research the team developed a novel imaging technique that can observe the tumor microenvironment directly. The imaging procedure leverages a mechanism where brain astrocytes take up elevated acetate levels and become hazardous reactive astrocytes. Using this mechanism in the imaging technique granted the research team unprecedented insight into the tumor microenvironment and opened the door to the development…

Continue Reading

TuesdayJan 23, 2024 9:45 am

Astrotech Corp. (NASDAQ: ASTC) Subsidiary AgLAB: Breakthrough Technology For Ag-Distillers

Astrotech subsidiary AgLAB demonstrates the capability of significant improvements in yields for large scale producers of hemp and cannabis CBD-THC oils using breakthrough mass spectrometry technology The company’s AgLAB 1000-D2(TM) mass spectrometer and the Maximum Value Process(TM) testing method (“AgLAB MVP(TM)”) allows large-scale distillers to analyze oils during processing, and make real-time adjustments to boost yields and potencies Field trials resulted in improved ending-weight yields by an average of 30%, which can translate into bottom-line profits Astrotech presented the AgLAB Maximum Value Process at last year’s MJBizCon in November, it is the premier global hemp and cannabis business conference and…

Continue Reading

MondayJan 22, 2024 10:54 am

Small Study Shows Existing Drug Could Reduce Opioid Administration After Surgery

A pilot study by researchers from the Medical University of South Carolina has revealed that an FDA-approved drug could help reduce the need for opioid administration after surgery. Scientists from the university’s Department of Anesthesia and Perioperative Medicine (MUSC) found that an already-approved drug called N-acetylcysteine (NAC) could reduce pain levels in patients after spinal surgery, thereby limiting the need for opioids. The pilot study involved spinal surgery patients who received traditional pain-relief treatments as well as NAC after surgery. The researchers found that these patients had lower pain scores and asked for fewer opioids after their spinal surgeries compared…

Continue Reading

MondayJan 22, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment

Significant improvements in both vision and cognition, sustained over three years, were reported with CNM-Au8 treatment in results from the long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis Michael Barnett, a key clinical advisor, hailed the results, observed long term and over and above background therapy. as “unprecedented” A drug that may halt MS disease progression or improve function on top of standard-of-care MS therapies would represent a significant milestone in drug development for this disease Clene will present the full clinical results for the LTE at the ninth annual Americas Committee for…

Continue Reading

FridayJan 19, 2024 1:32 pm

Study Suggests Pediatric Autism Could Be Linked to Umbilical Cord Lipid Levels at Birth

New research has looked into the link between the cord blood lipid levels, autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) symptomatology. ASD and ADHD are neurodevelopmental disorders that affect the central nervous system, which is responsible for language, movement, memory, focusing and social skills. It is common knowledge that early-life risk factors such as maternal inflammation and contaminant chemicals impact neurodevelopmental conditions, including ADHD and ASD. These conditions can cause changes in serological lipids, which make up about 60% of brain weight and are necessary for neurodevelopment. For their research, the investigators utilized lipidomic analysis data from the Barwon…

Continue Reading

ThursdayJan 18, 2024 1:42 pm

Scientists Discover Alzheimer’s Can Be Categorized into Five Subtypes

Researchers have determined that there are different types of Alzheimer’s after they studied proteins found in cerebrospinal fluid. Alzheimer’s is a common form of dementia. This progressive illness often starts with memory loss and causes patients to lose their ability to speak in its later stages. This greatly impacts their ability to engage in daily activities. An abnormal protein build-up, which results in the death of nerve cells, is said to be the primary cause of this progressive illness. The death of these cells in turn causes the loss of functions they provide, which robs patients of their ability to…

Continue Reading

WednesdayJan 17, 2024 3:15 pm

Ancient DNA Suggests Origins of Multiple Sclerosis in EU

A massive cache of ancient genomes has helped researchers trace the origins of a wide variety of the genetic traits that occur in modern Europeans. According to the ancient DNA, characteristics such as an increased risk of developing multiple sclerosis may have reached Europe more than 45,000 years ago in the genomes of people who migrated to the European continent in three distinct waves. The research findings suggest that differences in the dispersal patterns of ancient migrants may have resulted in some of the regional variation seen in specific traits, contradicting the theory that genetic differences could have have occurred…

Continue Reading

TuesdayJan 16, 2024 11:15 am

InvestorBrandNetwork Highlights PaxMedica Inc.’s (NASDAQ: PXMD) Video Release on Transformative ASD Study

In a significant development for the neurological disorder community, PaxMedica (NASDAQ: PXMD) has released an insightful video detailing the outcomes of its Phase 2 study on Autism Spectrum Disorder (“ASD”), initially published in the Annals of General Psychiatry. This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD. The study, a comprehensive 14-week randomized, double-blind, placebo-controlled trial, enrolled 52 boys aged 4–15 years with moderate to severe ASD. Focused on evaluating the efficacy and safety of…

Continue Reading

FridayJan 12, 2024 12:30 pm

Fruit Fly Study Opens Door to Novel Immunotherapy Approach Against Cancer

Researchers from UC Santa Barbara recently solved a mystery that had been unanswered for more than two decades and potentially opened a door to the development of novel immunotherapy protocols against cancer. After examining evidence from fruit flies, mice and humans over several decades, the scientists uncovered the fact that cannibalistic cells may be responsible for a rare human immunodeficiency. The study’s senior author, Professor Denise Montell, stated that the research used basic cell biology and human pathology to pave the way for a new cancer therapy. Montell is a UC Santa Barbara Duggan professor as well as a distinguished…

Continue Reading

ThursdayJan 11, 2024 10:44 am

TikTok Wants to Hit $17.5B in Online US Sales in 2024

TikTok plans to expand its operations in the American e-commerce sector to roughly $17.5 billion this year. TikTok, a product by ByteDance Limited, announced its goal in recent meetings focused on its progress. The achievement of this objective would put TikTok at a better strategic position to acquire an even larger share of the e-commerce market, which is currently held by Amazon.com Inc. Unlike strategies employed by peers such as Shein and Temu, TikTok shop centers blend convenient shopping experiences with online entertainment in the United States. This strategy encourages consumers to make impulse purchases. TikTok hopes to attract more…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000